Citations

Mayo Clinic

Clear

9374 citation(s) found for "Ly, Thomas".

Outcome of Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting
Hillis, Graham S. , Zehr, Kenton J., Williams, Amy W. , Schaff, Hartzell V. , Orzulak, Thomas A., Daly, Richard C. , Mullany, Charles J., Rodeheffer, Richard J. , Oh, Jae K. , Schaff, Hartzell

Circulation | July 7, 2006 | Volume: 114 | Issue: 1_supplement | Pages: No page available

10.1161/circulationaha.105.000661 | PMID 16820610 Get It

Background—There are few data regarding medium-term outcome of coronary artery bypass grafting (CABG) in patients with severe left ventricular (LV) systolic dysfunction, particularly in the modern era, and even less assessing preoperative factors that might identify patients at highest risk.Methods and Results—Three hundred seventy-nine consecutive patients with LV ejection fraction ≤35%, who underwent isolated first CABG between 1995 and 1999 were studied. Potential preoperative and perioperative predictors of outcome were recorded and patients followed-up for a median of 3.8 years. The primary study end-point was all-cause mortality. The 30-day, 1-year, and 3-year survival rates were 94.5%, 88%, and 81%, respectively. The independent predictors of mortality were preoperative estimated glomerular filtration rate (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.97 to 0.99 per mL/min/1.73m2;P<0.001) and age (HR, 1.03; 95% CI, 1.01 to 1.06 per year;P=0.005).Conclusions—Patients with significant LV systolic dysfunction undergoing isolated CABG using contemporary techniques have a good medium-term survival. Renal dysfunction is the strongest independent predictor of mortality.
Idiopathic Pulmonary Fibrosis
Flaherty, Kevin R. , Andrei, Adin‐Cristian , Murray, Susan , Fraley, Chris, Colby, Thomas V. , Lama, Vibha N. , Kazerooni, Ella A. , Gross, Barry H., Toews, Galen B., Travis, William D. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | July 6, 2006 | Volume: 174 | Issue: 7 | Pages: 803-809

10.1164/rccm.200604-488oc | PMID 16825656 Get It

Abstract Rationale and Hypothesis Idiopathic pulmonary fibrosis is a fatal disease with a variable rate of progression. We hypothesized that changes in distance walked and quantity of desaturation during a six-minute-walk test (6MWT) would add prognostic information to changes in FVC or diffusing capacity for carbon monoxide. Methods One hundred ninety-seven patients with idiopathic pulmonary fibrosis were evaluated. Desaturation during the 6MWT was associated with increased mortality even if a threshold of 88% was not reached. Baseline walk distance predicted subsequent walk distance but was not a reliable predictor of subsequent mortality in multivariate survival models. The predictive ability of serial changes in physiology varied when patients were stratified by the presence/absence of desaturation ⩽ 88% during a baseline 6MWT. For patients with a baseline saturation ⩽ 88% during a 6MWT, the strongest observed predictor of mortality was serial change in diffusing capacity for carbon monoxide. For patients with saturation &gt; 88% during their baseline walk test, serial decreases in FVC and increases in desaturation area significantly predicted subsequent mortality, whereas decreases in walk distance and in diffusing capacity for carbon monoxide displayed less consistent statistical evidence of increasing mortality in our patients. Conclusion These data highlight the importance of stratifying patients by degree of desaturation during a 6MWT before attributing prognostic value to serial changes in other physiologic variables.
Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803
Meyerhardt, Jeffrey A. , Heseltine, Denise, Niedzwiecki, Donna , Hollis, Donna, Saltz, Leonard B. , Nelson, Heidi , Whittom, Renaud , Hantel, Alexander, Schilsky, Richard L. , Fuchs, Charles S. , Mayer, Robert J. , Thomas, James P. , Saltz, Leonard , Meyerhardt, Jeffrey A , Niedzwiecki, Donna

Journal of Clinical Oncology | July 6, 2006 | Volume: 24 | Issue: 22 | Pages: 3535-3541

10.1200/jco.2006.06.0863 | PMID 16822843 Get It

Purpose Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown. Patients and Methods We conducted a prospective observational study of 832 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on various recreational physical activities approximately 6 months after completion of therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded patients who experienced recurrence or died within 90 days of their physical activity assessment. Results Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01. Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01). The benefit associated with physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or chemotherapy received. Moreover, the benefit remained unchanged even after excluding participants who developed cancer recurrence or died within 6 months of activity assessment. Conclusion Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.
Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer
Mahoney, Michelle R., Allmer, Cristine, Pitot, Henry C., Kim, George , Donehower, Ross C. , Fitch, Tom R., Erlichman, Charles , Philip, Philip A. , Thomas, James P. , Picus, Joel

Journal of Clinical Oncology | June 30, 2006 | Volume: 24 | Issue: 19 | Pages: 3069-3074

10.1200/jco.2005.05.3579 | PMID 16809731 Get It

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.
Lack of Evidence for an Association Between Hemodynamic Variables and Hematoma Growth in Spontaneous Intracerebral Hemorrhage
Jauch, Edward C. , Lindsell, Christopher J. , Barsan, William G. , Pancioli, Arthur , Brott, Thomas G. , Adeoye, Opeolu M , Khoury, Jane , Broderick, Joseph P.

Stroke | June 23, 2006 | Volume: 37 | Issue: 8 | Pages: 2061-2065

10.1161/01.str.0000229878.93759.a2 | PMID 16794216 Get It

Background and Purpose— Early hematoma expansion in spontaneous intracerebral hemorrhage (ICH) is associated with worse clinical outcome. We hypothesized that hemodynamic parameters are associated with the increase in hematoma volume owing to their relationship to blood vessel wall stresses. Methods— We performed a post hoc analysis of clinical and computed tomography (CT) data from patients enrolled in a prospective observational study of ICH patients presenting within 3 hours from symptom onset. Hematoma volumes were measured at hospital arrival and at 1 and 20 hours from presentation. Blood pressure and heart rate, recorded at 19 time points between presentation and 20 hours, were used to derive hemodynamic variables. Multivariable logistic-regression models were constructed to assess the relation between hemodynamic parameters and hematoma growth, adjusted for clinical covariates. Results— From the original study, 98 patients underwent baseline and 1-hour CT scans; of these, 65 had 20-hour CT scans. Substantial hematoma growth was observed in 28% within the first hour. Of the 65 patients not undergoing surgery within 20 hours, 37% experienced hematoma growth by 20 hours. Neither baseline or peak hemodynamic parameters nor changes in hemodynamic parameters were significantly associated with hematoma growth at either 1 or 20 hours. Conclusions— We found no blood pressure or heart rate parameters, individually or in combination, that were associated with hematoma growth. Our data suggest the influence of hemodynamic parameters on vessel wall stress to be an unlikely target for intervention in reducing the risk of early hematoma growth in ICH.
Schistosoma mansoni infection in eosinophil lineage–ablated mice
Swartz, Jonathan M. , Dyer, Kimberly D., Cheever, Allen W., Ramalingam, Thirumalai R. , Pesnicak, Lesley, Domachowske, Joseph B. , Lee, James J. , Lee, Nancy A., Foster, Paul S. , Wynn, Thomas A. , Rosenberg, Helene F.

Blood | June 14, 2006 | Volume: 108 | Issue: 7 | Pages: 2420-2427

10.1182/blood-2006-04-015933 | PMID 16772607 Get It

AbstractWe explore the controversial issue of the role of eosinophils in host defense against helminthic parasites using the established Schistosoma mansoni infection model in 2 novel mouse models of eosinophil lineage ablation (ΔdblGATA and TgPHIL). No eosinophils were detected in bone marrow of infected ΔdblGATA or TgPHIL mice, despite the fact that serum IL-5 levels in these infected mice exceeded those in infected wild type by approximately 4-fold. Liver granulomata from infected ΔdblGATA and TgPHIL mice were likewise depleted of eosinophils compared with those from their respective wild types. No eosinophil-dependent differences in granuloma number, size, or fibrosis were detected at weeks 8 or 12 of infection, and differential accumulation of mast cells was observed among the ΔdblGATA mice only at week 12. Likewise, serum levels of liver transaminases, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) increased in all mice in response to S mansoni infection, with no eosinophil-dependent differences in hepatocellular damage observed. Finally, eosinophil ablation had no effect on worm burden or on egg deposition. Overall, our data indicate that eosinophil ablation has no impact on traditional measures of disease in the S mansoni infection model in mice. However, eosinophils may have unexplored immunomodulatory contributions to this disease process.
Response to Recommendations for Blood Pressure Measurement in Human and Experimental Animals; Part 1: Blood Pressure Measurement in Humans and Miscuffing: A Problem With New Guidelines: Addendum
Hall, John E. , Graves, John W., Hill, Martha, Kurtz, Theodore W. , Sheps, Sheldon G., Roccella, Edward J., Pickering, Thomas G. , Appel, Lawrence J. , Falkner, Bonita E. , Hill, Martha, Jones, Daniel W.

Hypertension | June 13, 2006 | Volume: 48 | Issue: 1 | Pages: No page available

10.1161/01.hyp.0000229662.44490.89 Get It

Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis
Friedman, Paul A. , McClelland, Robyn L. , Bamlet, William R. , Acosta, Helbert , Kessler, David J. , Munger, Thomas M. , Kavesh, Neal G., Wood, Mark, Daoud, Emile G. , Massumi, Ali, Schuger, Claudio , Shorofsky, Stephen R., Wilkoff, Bruce L. , Glikson, Michael , Wood, Mark, Glikson, Michael , Bamlet, William R

Circulation | June 13, 2006 | Volume: 113 | Issue: 25 | Pages: 2871-2879

10.1161/circulationaha.105.594531 | PMID 16769912 Get It

Background— Delivery of inappropriate shocks caused by misdetection of supraventricular tachycardia (SVT) remains a substantial complication of implanted cardioverter/defibrillator (ICD) therapy. Whether use of optimally programmed dual-chamber ICDs lowers this risk compared with that in single-chamber ICDs is not clear. Methods and Results— Subjects with a clinical indication for ICD (n=400) at 27 participating centers received dual-chamber ICDs and were randomly assigned to strictly defined optimal single- or dual-chamber detection in a single-blind manner. Programming minimized ventricular pacing. The primary end point was the proportion of SVT episodes inappropriately detected from the time of programming until crossover or end of study. On a per-episode basis, 42% of the episodes in the single-chamber arm and 69% of the episodes in the dual-chamber arm were due to SVT. Mortality (3.5% in both groups) and early study withdrawal (14% single-chamber, 11% dual-chamber) were similar in both groups. The rate of inappropriate detection of SVT was 39.5% in the single-chamber detection arm compared with 30.9% in the dual-chamber arm. The odds of inappropriate detection were decreased by almost half with the use of the dual-chamber detection enhancements (odds ratio, 0.53; 95% confidence interval, 0.30 to 0.94; P =0.03). Conclusions— Dual-chamber ICDs, programmed to optimize detection enhancements and to minimize ventricular pacing, significantly decrease inappropriate detection.
Is Self‐Disclosure Part of the Genetic Counselor's Clinical Role?
Thomas, Brittany C. , Veach, Patricia McCarthy , LeRoy, Bonnie S.

Journal of Genetic Counseling | June 12, 2006 | Volume: 15 | Issue: 3 | Pages: 163-177

10.1007/s10897-006-9022-y | PMID 16770705 Get It

The role of genetic counselor self‐disclosure in clinical practice is unclear as there are few published investigations of this issue. In the present study, 11 genetic counselors who previously received genetic services were interviewed about their opinions and use of disclosure. Several themes were extracted from their responses. All participants reportedly disclosed to patients; however, not all disclosed their receipt of genetic services. Patient requests for self‐disclosure influenced many participants’ disclosure decisions. Opinions regarding potential benefits of disclosure varied. Nearly all participants stressed the importance of self‐disclosing judiciously, stating that it may be counterproductive to client goal attainment. Four individuals with expertise in genetic counseling and psychotherapy were invited to react to these themes and to provide their opinions of self‐disclosure. Their views are compared to those of the present sample, and practice and research recommendations are given.